A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL184 Administered Orally to Subjects With Advanced Malignancies.

Trial Profile

A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL184 Administered Orally to Subjects With Advanced Malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jul 2015

At a glance

  • Drugs Cabozantinib (Primary)
  • Indications Solid tumours; Thyroid cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 02 Jun 2013 Long-term follow-up results in patients with progressive, metastatic medullary thyroid cancer presented at ASCO 2013, according to an Exelixis media release.
    • 26 Feb 2013 Actual end date Jul 2012 added as reported by ClinicalTrials.gov.
    • 26 Feb 2013 Actual end date Jul 2012 added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top